



Published in final edited form as:

*Clin Pharmacol Ther.* 2022 February ; 111(2): 366–372. doi:10.1002/cpt.2309.

## Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on *MT-RNR1* Genotype

John Henry McDermott<sup>1,2,†</sup>, Joshua Wolf<sup>3,†</sup>, Keito Hoshitsuki<sup>4</sup>, Rachel Huddart<sup>5</sup>, Kelly E. Caudle<sup>6</sup>, Michelle Whirl-Carrillo<sup>5</sup>, Peter S. Steyger<sup>7</sup>, Richard J. H. Smith<sup>8</sup>, Neal Cody<sup>9,10</sup>, Cristina Rodriguez-Antona<sup>11</sup>, Teri E. Klein<sup>5,12</sup>, William G. Newman<sup>1,2,\*</sup>

<sup>1</sup>Manchester Centre for Genomic Medicine, St. Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK

<sup>2</sup>Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK

<sup>3</sup>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

<sup>4</sup>School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

<sup>5</sup>Department of Biomedical Data Science, Stanford University, Stanford, California, USA

<sup>6</sup>Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

<sup>7</sup>Translational Hearing Center, Biomedical Sciences, Creighton University, National Center for Rehabilitative Auditory Research, VA Portland Health Care System, Portland, Oregon, USA

<sup>8</sup>Molecular Otolaryngology and Renal Research Laboratories, Department of Otolaryngology, Internal Medicine (Nephrology), Pediatrics and Molecular Physiology & Biophysics, University of Iowa, Iowa City, Iowa, USA

\*Correspondence: William Newman (william.newman@manchester.ac.uk).

†These authors shared first authorship.

### CONFLICTS OF INTEREST

N.C. is an assistant laboratory director in the pharmacogenomics division at Mount Sinai Genomics Inc, DBA Sema4. All other authors declared no competing interests for this work.

### DISCLAIMER

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making, as well as to identify questions for further research. New evidence may have emerged since the time a guideline was submitted for publication. Guidelines are updated periodically on <https://cpicpgx.org/guidelines/> and it is the responsibility of the guideline user to consult this website for updates. Guidelines are limited in scope and are not applicable to interventions or diseases not specifically identified. Guidelines do not account for all individual variation among patients and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health care provider to determine the best course of treatment for the patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be solely made by the clinician and the patient. CPIC assumes no responsibility for any injury to persons or damage to property related to any use of CPIC's guidelines, or for any errors or omissions.

### SUPPORTING INFORMATION

Supplementary information accompanies this paper on the *Clinical Pharmacology & Therapeutics* website ([www.cpt-journal.com](http://www.cpt-journal.com)).

<sup>9</sup>Department of Genetics and Genomic Sciences, Ichan School of Medicine at Mount Sinai, New York, New York, USA

<sup>10</sup>Sema4, Stamford, Connecticut, USA

<sup>11</sup>Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

<sup>12</sup>Department of Medicine, Stanford University, Stanford, California, USA

## Abstract

Aminoglycosides are widely used antibiotics with notable side effects, such as nephrotoxicity, vestibulotoxicity, and sensorineural hearing loss (cochleotoxicity). *MT-RNR1* is a gene that encodes the 12s rRNA subunit and is the mitochondrial homologue of the prokaryotic 16s rRNA. Some *MT-RNR1* variants (i.e., m.1095T>C; m.1494C>T; m.1555A>G) more closely resemble the bacterial 16s rRNA subunit and result in increased risk of aminoglycoside-induced hearing loss. Use of aminoglycosides should be avoided in individuals with an *MT-RNR1* variant associated with an increased risk of aminoglycoside-induced hearing loss unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of aminoglycosides based on *MT-RNR1* genotype (updates at <https://cpicpgx.org/guidelines/> and [www.pharmgkb.org](http://www.pharmgkb.org)).

The purpose of this Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline is to provide information to allow the interpretation of selected *MT-RNR1* genotype results to guide healthcare providers on the proper use of aminoglycosides. Detailed guidelines for use of these agents, diagnostic testing, as well as analyses of cost effectiveness, are beyond the scope of this document. CPIC guidelines are periodically updated at [www.cpicpgx.org](http://www.cpicpgx.org).

## FOCUSED LITERATURE REVIEW

A systematic literature review focused on *MT-RNR1* genotypes and aminoglycoside use was conducted (details in the Supplementary Material).

## DRUGS: AMINOGLYCOSIDES

### Background

Aminoglycosides are a large class of antibiotics which are widely used clinically around the world for the treatment of infection. Their safety profile is well-understood, they have proven efficacy, and can be used in combination with other antibiotics. Streptomycin was the first aminoglycoside antibiotic, isolated in 1943. Since then, the class has grown significantly to include many natural and semisynthetic agents. They are typically administered by intravenous or intramuscular injection for treatment of serious Gram-negative bacterial infections or as synergistic treatment for serious Gram-positive bacterial infections, and topically for other purposes. Therapeutic dose monitoring is required because

pharmacokinetics vary between individuals and high levels are associated with greater toxicity.

Aminoglycoside antibiotics confer their bactericidal effect through the inhibition of protein synthesis by binding to the 16s ribosomal RNA (rRNA) subunit of the bacterial 30S ribosome.<sup>1</sup> The 30S ribosome is responsible for messenger RNA (mRNA) translation within the prokaryotic cell. The 16s component recognizes and binds the Shine-Dalgarno sequence, which ensures the ribosome and the mRNA align effectively allowing protein synthesis to commence.<sup>2</sup> If the 16s rRNA subunit is bound to an aminoglycoside, this will severely interrupt normal protein synthesis and result in mistranslation by inducing codon misreading, causing error prone protein synthesis.<sup>3</sup>

In addition to nephrotoxicity, sensorineural hearing loss (cochleotoxicity) and vestibulotoxicity are well-recognized ototoxic side effects of aminoglycoside antibiotics. These side effects are typically dose-dependent and are observed in patients who receive high doses of aminoglycosides for a protracted period. However, certain individuals appear to have a predisposition toward aminoglycoside-induced hearing loss (AIHL), with reports of single doses causing profound bilateral sensorineural hearing loss.<sup>4</sup> Unlike many actionable pharmacogenetic traits that affect the metabolism of a drug and thus drug exposure, the variants in the gene under consideration here predispose individuals to a severe AIHL after exposure to current standard recommended doses of aminoglycosides. This evidence review will focus on that relationship.

## GENE: *MT-RNR1*

**Background**—The human mitochondrial genome contains 37 genes; 13 encode components of the mitochondrial respiratory chain, whereas the other 24 encode a mature RNA product. Twenty-two of these mature RNA products are mitochondrial tRNA molecules, one is a 16s rRNA subunit, and one is a 12s rRNA subunit. These subunits are necessary for the translation of mRNAs into mitochondrial proteins.<sup>5</sup>

The 12s rRNA subunit is encoded by the *MT-RNR1* gene and is the mitochondrial homologue of the prokaryotic 16s rRNA subunit. Early family studies identified that the predisposition toward AIHL appeared to be inherited down the maternal lineage, in an extra-nuclear (mitochondrial) inheritance pattern. In 1993, mitochondrial sequencing of 4 families with AIHL identified the m.1555A>G variant in affected individuals in each family. This variant is in a highly conserved region of the 12s rRNA subunit, which has 2 single stranded regions separated by 2 stem-loops. In the bacterial homologue, this region is where mRNAs are decoded, and it is where aminoglycosides bind to confer their therapeutic, bactericidal effect. Variants in *MT-RNR1*, which pre-dispose to AIHL, appear to cause the 12s rRNA subunit to more closely resemble the bacterial 16s rRNA subunit, thus allowing aminoglycosides to bind more readily.<sup>6–8</sup> Other than m.1555A>G, additional variants with sufficient evidence to support a drug-variant interaction are m.1095T>C and m.1494C>T. As such, this guideline concentrates on providing prescribing guidance in the context of these three variants. The *MT-RNR1* allele frequency table<sup>9,10</sup> provides allele frequencies based on bio-geographical groups.

In addition to m.1555A>G, many additional *MT-RNR1* variants have been proposed as being associated with AIHL (*MT-RNR1* allele functionality table<sup>9,10</sup>). However, many of these variants are only described in single studies and therefore there is insufficient evidence to support their risk for AIHL. The lack of inclusion of a variant within this guideline should not be interpreted as it being not associated with AIHL; rather, there is insufficient evidence to determine its associated risk with AIHL at this time.

**Genetic test interpretation**—Whereas most nuclear genes exist in diploidy, with one copy found on each autosome, there is a copy of each mitochondrial gene within each mitochondrion. Most cells contain ~ 100 mitochondria, but those cells with high energy requirements can have up to 1,000. Unlike with many pharmacogenetic guidelines, there is no metabolizer status assignment based on the patient's diploidy. Rather, the presence of a pathogenic *MT-RNR1* variant in an individual can be interpreted as conferring susceptibility to AIHL.

The assignment of a pathogenic variant in *MT-RNR1* is based on multiple lines of evidence, including functional data, *in vitro* data, case-control data, and population allele frequency (*MT-RNR1* allele functionality and frequency tables<sup>9</sup>). It should be noted that one of the limitations inherent in commercially available genotyping tests is that very rare variants will not generally be included or interrogated by these tests.

This CPIC recommendation assumes that genetic testing has been performed and that an *MT-RNR1* variant has been detected, irrespective of the methodology of testing. The identification of an *MT-RNR1* variant that is known to predispose to AIHL is sufficient to assign a phenotype status, but the absence of a variant does not indicate no risk of AIHL.

**Available genetic test options**—Molecular genetic testing of *MT-RNR1* is available from numerous clinical testing laboratories (see Genetic Testing Registry (GTR): [https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=4549\[geneid\]](https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=4549[geneid])).

**Incidental findings**—In addition to predisposing to AIHL, there is weak evidence that the m.1555A>G variant is also associated with non-aminoglycoside-related sensorineural hearing loss.<sup>11</sup> However, this relationship is not clear, and a population-based cohort study found that hearing in individuals with the m.1555A>G, identified from a birth cohort study, was not significantly different from those without the variant at the age of 45 years.<sup>12</sup> As such, there is insufficient evidence to support additional hearing assessments in individuals with *MT-RNR1* variants that predispose to AIHL if they have not been exposed to an aminoglycoside. There are no other known health-related associations that would require disclosure to individuals before *MT-RNR1* genetic testing.

Due to the mitochondrial inheritance pattern of *MT-RNR1*, the identification of a clinically relevant *MT-RNR1* variant in an individual will be of relevance to any of their maternal relatives (i.e., mother, siblings, mother's siblings, and maternal grandmother) and to all of the children of a woman identified to carry the variant. This should be communicated to the patient when a clinically relevant genotype is identified and the advice to avoid aminoglycosides should be cascaded to the relevant individuals within the family. Advice

from a clinical genetics service can be sought to support the cascading of information within the family.

**Other considerations—***MT-RNR1* variants were historically described as exclusively homoplasmic variants, meaning the same variant was seen in every mitochondrion. However, this likely represented an ascertainment bias due to the choice of genotyping technology. Increasingly sensitive molecular approaches, which allow quantification, more readily facilitate the detection of *MT-RNR1* heteroplasmy, the presence of more than one type of mitochondrial genome within a cell. There are now several reports of variable levels of *MT-RNR1* heteroplasmy for the m.1555A>G variant.<sup>13–15</sup> The reasonable clinical question raised by the phenomenon of heteroplasmy is whether there is a threshold at which the administration of an aminoglycoside becomes acceptable. Based on the available literature, at present, there is not sufficient evidence to define a level of heteroplasmy where aminoglycoside administration becomes safe, especially as the mutational load may differ from tissue to tissue and be dependent upon the genotyping technique utilized. As such, we have not tailored this guideline based on the level of heteroplasmy. Rather, we recommend that if a relevant *MT-RNR1* variant is detected, the guidance should be followed as set out for a homoplasmic variant.

**Linking genetic variability to variability in drug-related phenotypes—**Potentially pathogenic *MT-RNR1* variants are present at a relatively low frequency in the population (*MT-RNR1* allele functionality and frequency tables<sup>9</sup>). As such, many of the studies which investigate the relationship between *MT-RNR1* variants and AIHL have methodological flaws. A large number of clinical studies have been published proposing an association between the *MT-RNR1* variants and AIHL (Table S1).<sup>16–20</sup> The majority of these are small retrospective cohort studies, where authors have identified groups with a high prevalence of hearing loss and have subsequently performed genotyping of *MT-RNR1*. Prescribing data detailing aminoglycoside administration is then used to draw conclusions about the relationship between the variant and AIHL. When reviewing the literature, we were conscious that such sampling bias can lead to claims for causality that do not meet the necessary evidence level.<sup>21</sup> Establishing a causal and temporal relationship between *MT-RNR1* variants and AIHL is challenging. Furthermore, interpretation guidance for mitochondrial variants does not consider the impact of a phenotype in the context of a drug exposure.<sup>22</sup> Despite these issues, there was sufficient and consistent evidence to assign actionability to the m.1555A>G and m.1494C>T variants with high levels of evidence and the m.1095T>C variant with a moderate level of evidence (Table 1, Table S1). The m.827A>G variant, despite weak evidence proposing an association with AIHL, has too high a population frequency in certain biogeographic groups to be classified as associated with AIHL *MT-RNR1* allele functionality and frequency tables.<sup>9</sup> We therefore classify m.827A>G as conferring no additional (normal) risk for AIHL at this time.

**Therapeutic recommendations—**The critical pharmacogenetics recommendation for a person with an *MT-RNR1* variant, which predisposes to AIHL is that aminoglycoside antibiotics are relatively contraindicated, meaning that aminoglycosides should be avoided unless the increased risk of hearing loss is outweighed by the severity of infection and

lack of safe or effective alternative therapies (Table 2). There is insufficient evidence to suggest that the adverse drug reaction may be more profound with some members of the aminoglycoside class than others. As such, this guidance covers all aminoglycoside antibiotics irrespective of class. We provide a strong recommendation that carriers of *MT-RNR1* variants that predispose to AIHL should avoid aminoglycosides unless the increased risk of permanent hearing loss is outweighed by the risk of infection without safe or effective alternative therapies (see section Considerations for aminoglycoside use in patients at increased risk of AIHL). If no effective alternative to an aminoglycoside is thought to be available, we advise use for the shortest possible time, consultation with an infectious disease expert for alternative approaches, therapeutic drug monitoring, and frequent assessment for hearing loss, both during and after therapy, in consultation with an audiological physician.

An individual with no detectable *MT-RNR1* variant or carrying *MT-RNR1* variants not considered to be predisposing to AIHL (normal risk), including the m.827A>G variant, should still be considered at risk of AIHL. In addition to *MT-RNR1*, AIHL is often associated with other risk factors, such as prematurity, renal impairment, severe inflammatory response syndrome, prolonged therapy regimens, and supratherapeutic plasma concentrations.<sup>23,24</sup> As such, irrespective of the presence of an *MT-RNR1* variant, which predisposes to AIHL, precautions such as renal monitoring, therapeutic drug monitoring, and utilizing the lowest effective dose should be applied. Finally, if an individual with an actionable *MT-RNR1* variant has previously received aminoglycosides and not developed AIHL, this does not preclude them from developing AIHL with subsequent doses.

### **Considerations for aminoglycoside use in patients at increased risk of AIHL.**

—For the purposes of this guideline, appropriateness for use of aminoglycoside antibiotics can be considered for three scenarios. First, an equally or more effective agent is available for the condition; second, there is reason to believe that an aminoglycoside might lead to superior outcomes, but evidence is poor, the effect-size is small, or the outcome is not clinically meaningful; and third, there is good evidence for significantly superior efficacy of an aminoglycoside-containing treatment regimen for a clinically meaningful outcome.

Examples of the first scenario include treatment of bloodstream or urinary tract infection susceptible to other antibiotics, and empiric use for treatment of fever or suspected infection in a patient without risk factors for broadly resistant Gram-negative infection.<sup>25–29</sup> In these circumstances, an aminoglycoside is typically being chosen for reasons of cost, antimicrobial stewardship, or personal/institutional preference. The panel recommends against use of an aminoglycoside in this scenario for individuals at increased risk of AIHL due to the presence of an *MT-RNR1* variant.

Examples of the second scenario include initial adjunctive empiric therapy for severe sepsis in adults and neonates,<sup>30</sup> serious infections in patients at high risk of broadly resistant Gram-negative infection, treatment of severe tularemia, plague and brucellosis, and as a component of therapy for enterococcal or streptococcal endocarditis.<sup>31–36</sup> In this scenario, the panel recommends that clinicians seek expert opinion about alternative options and use their best judgment to determine the appropriateness of aminoglycoside use, including



consideration of patient preferences and comorbidities, and accounting for the risk of AIHL. If used, the patient or patient's family should be informed of the increased risk of AIHL and the aminoglycoside should be used for the shortest possible period with appropriate precautions as detailed below.

Examples of the third scenario include combination therapy for extensively drug resistant tuberculosis where other effective agents are unavailable, treatment of Gram-negative organisms resistant to all available alternative therapies, and treatment of serious infections caused by *Mycobacterium abscessus* or other highly resistant *Mycobacteria* spp.<sup>33,37,38</sup> In this scenario, the panel recommends seeking expert opinion about alternative options, and use of an aminoglycoside for the shortest possible period with appropriate precautions as detailed below.

In all cases, an aminoglycoside used in patients at increased risk of AIHL due to the presence of an *MT-RNR1* variant should be administered for the shortest possible period, under expert supervision, with therapeutic drug and ototoxicity monitoring, and with clinical audiovestibular assessment performed during and after treatment. Irrespective of whether an individual carries a pathogenic *MT-RNR1* variant, all patients who receive aminoglycoside antibiotics, especially those prescribed prolonged courses, should be monitored for ototoxicity in line with existing local and international guidelines.<sup>39,40</sup>

As detailed below, administration of an aminoglycoside by a route other than intravenous or intramuscular may reduce, but not eliminate, the risk of AIHL. So, although there is insufficient evidence to determine the impact of this strategy, it might be considered in a clinically appropriate setting if aminoglycoside use is unavoidable in an individual at increased risk. For example, in a case of mycobacterial lung infection with no acceptable alternative therapy, administration of the drug by the inhaled route might be preferred if it is expected to be efficacious. If any hearing loss or vestibular dysfunction is identified, appropriate rehabilitation should be undertaken. Expert infectious diseases and audiology opinion is recommended in all cases as new information about alternative approaches may be available.

**Alternative routes of aminoglycoside administration.**—Aminoglycosides are highly bioavailable by intramuscular, intravenous, and intraperitoneal administration, so these guidelines apply similarly to each of these routes.<sup>41,42</sup> However, bioavailability of aminoglycosides by enteral, inhaled, topical, intrathecal, or intraventricular routes, or by bladder irrigation is lower and it is unknown whether administration by any of these other routes would routinely cause ototoxicity in patients at increased risk of AIHL.

Inhaled administration of aminoglycosides is associated with significant systemic exposure (~ 10–20%) and vestibulocochlear toxicity has been described, albeit usually in the presence of renal dysfunction, so avoidance may be considered in patients with increased risk *MT-RNR1* variants.<sup>43–49</sup> Similarly, systemic exposure and ototoxicity have been reported following use of orthopedic cement containing aminoglycosides, and avoidance of use may be considered in patients with increased risk *MT-RNR1* variants.<sup>50</sup> There are also reports of hearing loss after intrathecal or intraventricular administration of gentamicin or

streptomycin, but the potential role of *MT-RNR1* variants in the risk of this type of AIHL is unknown.<sup>51</sup> In contrast to these, enteral and topical administration of aminoglycosides typically has absolute bioavailability < 1% so is unlikely to cause AIHL, even in patients at increased risk.<sup>52</sup> Absorption of aminoglycosides from the gastrointestinal tract may be elevated in the presence of severe epithelial damage, such as in patients with severe gastrointestinal graft vs. host disease or large areas of deep skin burns, so caution is advised in that setting.<sup>53–55</sup> As in all patients, topical otic use of an aminoglycoside is relatively contraindicated in the presence of a perforated tympanic membrane because of the high risk of ototoxicity, but is unlikely to lead to AIHL in other circumstances and is not known to be associated with *MT-RNR1* variants.<sup>56–58</sup> Minimal systemic absorption of aminoglycosides has been documented from intravesicular administration as bladder washouts for treatment or prevention of urinary tract infections, but few data are available.<sup>59,60</sup>

**Pediatrics.**—These recommendations are not age-based and should apply to any individual with an *MT-RNR1* AIHL-associated genotype where administration of an aminoglycoside is being considered. As hearing, listening, and spoken language skills continue to develop in infants and children, the impact of aminoglycoside administration in children with an actionable *MT-RNR1* variant is likely to be greater than in the adult population.<sup>61</sup>

**Recommendations for incidental findings**—Not applicable.

#### Other considerations

**Implementation of this guideline.**—The guideline supplement contains resources that can be used within electronic health records to assist clinicians in applying genetic information to patient care for the purpose of drug therapy optimization (see Resources to incorporate pharmacogenetics into an electronic health record with clinical decision support sections of supplement).

### POTENTIAL BENEFITS AND RISKS FOR THE PATIENT

As aminoglycosides are commonly used worldwide, *MT-RNR1* genotype-guided antibiotic prescribing has the potential to reduce the occurrence rates of AIHL. This guidance emphasizes that aminoglycosides should be avoided unless the increased risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies. In the rare cases where aminoglycosides are the only antibiotic of choice, it is highly likely that the risk of inadequately treated infection would outweigh the increased risk of ototoxicity. Where *MT-RNR1* genotyping is to be integrated into clinical care, efforts should be made to design clinical pathways, which consider the changes required if an *MT-RNR1* variant that predisposes to AIHL is identified.

#### CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC TESTS

Rare *MT-RNR1* and uncertain risk variants are typically not included in common genotyping tests and patients are therefore assigned the “reference” or “wild-type” allele by default. Thus, an assigned “reference” allele may in rare cases harbor an increased risk



variant. Similar to all diagnostic tests, genetic tests are one of several pieces of clinical information that should be considered before initiating drug therapy.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

The authors acknowledge the critical input of Dr. Mary V. Relling (St. Jude Children's Research Hospital) and the members of the Clinical Pharmacogenetics Implementation Consortium (CPIC).

### FUNDING

This work was funded by the National Institutes of Health (NIH) for CPIC (K.E.C. and T.E.K. U24HG010135) and PharmGKB (R.H., T.E.K., and M.W.-C., U24HG010615). K.H. is supported by the National Institutes of Health grant TL1TR001858 and the Rho Chi Society and American Foundation for Pharmaceutical Education. W.G.N. is supported by the Manchester NIHR BRC (IS-BRC-1215-20007). P.S.S. is supported by NIDCD R01s: DC004555 and DC016680. RJHS is supported by NIDCD R01s: DC002842, DC012049, and DC017955. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH).

## REFERENCES

1. Kotra LP, Haddad J & Mobashery S Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. *Antimicrob. Agents Chemother* 44, 3249–3256 (2000). [PubMed: 11083623]
2. Malys N Shine-Dalgarno sequence of bacteriophage T4: GAGG prevails in early genes. *Mol. Biol. Rep* 39, 33–39 (2012). [PubMed: 21533668]
3. Davis BD, Chen LL & Tai PC Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides. *Proc. Natl. Acad. Sci. USA* 83, 6164–6168 (1986). [PubMed: 2426712]
4. Dean L Gentamicin therapy and MT-RNR1 genotype. In: *Medical Genetics Summaries* (eds. Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS & Kattman BL et al.) (National Center for Biotechnology Information, Bethesda, MD, 311–315 2021).
5. Yang LI et al. Species identification through mitochondrial rRNA genetic analysis. *Sci. Rep* 4, 4089 (2014). [PubMed: 24522485]
6. Ryu DH & Rando RR Decoding region bubble size and aminoglycoside antibiotic binding. *Bioorg. Med. Chem. Lett* 12, 2241–2244 (2002). [PubMed: 12127547]
7. Qian Y & Guan MX Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. *Antimicrob. Agents Chemother* 53, 4612–4618 (2009). [PubMed: 19687236]
8. Hamasaki K & Rando RR Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. *Biochemistry* 36, 12323–12328 (1997). [PubMed: 9315872]
9. CPIC. CPIC® Guideline for Aminoglycosides and MT-RNR1. <https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/>.
10. PharmGKB. PGx Gene-specific Information Tables. <<https://www.pharmgkb.org/page/pgxGeneRef>>.
11. Estivill X et al. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. *Am. J. Hum. Genet* 62, 27–35 (1998). [PubMed: 9490575]
12. Rahman S et al. Hearing in 44–45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study. *BMJ Open* 2, e000411 (2012).

13. del Castillo FJ et al. Heteroplasmy for the 1555A>G mutation in the mitochondrial 12S rRNA gene in six Spanish families with non-syndromic hearing loss. *J. Med. Genet* 40, 632–636 (2003). [PubMed: 12920080]
14. Kirichenko TV et al. Data on association of mitochondrial heteroplasmy and cardiovascular risk factors: comparison of samples from Russian and Mexican populations. *Data Brief* 18, 16–21 (2018). [PubMed: 29896485]
15. El-Schahawi M et al. Two large Spanish pedigrees with nonsyndromic sensorineural deafness and the mtDNA mutation at nt 1555 in the 12s rRNA gene. *Neurology* 48, 453–456 (1997). [PubMed: 9040738]
16. Usami S-I et al. Genetic and clinical features of sensorineural hearing loss associated with the 1555 mitochondrial mutation. *Laryngoscope* 107, 483–490 (1997). [PubMed: 9111378]
17. Fischel-Ghodsian N et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. *Am. J. Otolaryngol* 18, 173–178 (1997). [PubMed: 9164619]
18. Usami S et al. Prevalence of mitochondrial gene mutations among hearing impaired patients. *J. Med. Genet* 37, 38–40 (2000). [PubMed: 10633132]
19. Li Z et al. Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss. *Hum. Genet* 117, 9–15 (2005). [PubMed: 15841390]
20. Shen Z et al. Frequency and spectrum of mitochondrial 12S rRNA variants in 440 Han Chinese hearing impaired pediatric subjects from two otology clinics. *J. Transl. Med* 9, 4 (2011). [PubMed: 21205314]
21. MacArthur DG et al. Guidelines for investigating causality of sequence variants in human disease. *Nature* 508, 469–476 (2014). [PubMed: 24759409]
22. McCormick EM et al. Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation. *Hum. Mutat* 41, 2028–2057 (2020). [PubMed: 32906214]
23. Gopel W et al. Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. *BMC Pediatr.* 14, 210 (2014). [PubMed: 25155176]
24. Koo J-W et al. Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity. *Sci. Transl. Med* 7, 298ra118 (2015).
25. Gupta K et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin. Infect. Dis* 52, e103–e120 (2011). [PubMed: 21292654]
26. Heffernan AJ et al. beta-lactam antibiotic versus combined beta-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. *Int. J. Antimicrob. Agents* 55, (2020), 105839. [PubMed: 31704215]
27. Zohar I, Schwartz O, Yossepowitch O, David SSB & Maor Y Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae. *J. Antimicrob. Chemother* 75, 458–465 (2020). [PubMed: 31691817]
28. Wattier RL, Levy ER, Sabnis AJ, Dvorak CC & Auerbach AD Reducing second gram-negative antibiotic therapy on pediatric oncology and hematopoietic stem cell transplantation services. *Infect. Control Hosp. Epidemiol* 38, 1039–1047 (2017). [PubMed: 28758610]
29. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management et al. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics* 128, 595–610 (2011). [PubMed: 21873693]
30. Cross CP, Liao S, Urdang ZD, Srikanth P, Garinis AC & Steyger PS Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure. *Int. J. Pediatr. Otorhinolaryngol* 79, 1915–1919 (2015). [PubMed: 26384832]
31. Liljedahl Prytz K, Prag M, Fredlund H, Magnuson A, Sundqvist M & Kallman J Antibiotic treatment with one single dose of gentamicin at admittance in addition to a beta-lactam antibiotic

- in the treatment of community-acquired bloodstream infection with sepsis. *PLoS One* 15, e0236864 (2020). [PubMed: 32730359]
32. Yang R Plague: recognition, treatment, and prevention. *J. Clin. Microbiol* 56(1), e01519–17 (2018). [PubMed: 29070654]
  33. Hsu AJ & Tamma PD Treatment of multidrug-resistant Gram-negative infections in children. *Clin. Infect. Dis* 58, 1439–1448 (2014). [PubMed: 24501388]
  34. Micek ST et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. *Antimicrob. Agents Chemother* 54, 1742–1748 (2010). [PubMed: 20160050]
  35. Bossi P et al. Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. *Euro. Surveill* 9, E9–10 (2004). [PubMed: 15677845]
  36. Corbel MJ Brucellosis in humans and animals. (World Health Organization, Geneva, Switzerland, 2006).
  37. Daley CL et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Clin. Infect. Dis* 71, 905–913 (2020). [PubMed: 32797222]
  38. Nahid P et al. Treatment of drug-resistant tuberculosis. an official ATS/CDC/ERS/IDSA clinical practice guideline. *Am. J. Respir. Crit. Care Med* 200, e93–e142 (2019). [PubMed: 31729908]
  39. Audiology. American Academy of Audiology Position Statement and Clinical Practice Guidelines Ototoxicity Monitoring. Vol. 2021 (American Academy of Audiology, 2009).
  40. American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. (American Speech-Language-Hearing Association, 1994).
  41. Tang W, Cho Y, Hawley CM, Badve SV & Johnson DW The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis. *Perit. Dial. Int* 34, 219–226 (2014). [PubMed: 24385334]
  42. Varghese JM et al. Pharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study). *Clin. J. Am. Soc. Nephrol* 7, 1249–1256 (2012). [PubMed: 22700884]
  43. Kaufman AC & Eliades SJ Vestibulotoxicity in a patient without renal failure after inhaled tobramycin. *Am. J. Otolaryngol* 40, 456–458 (2019). [PubMed: 30910434]
  44. Geller DE, Konstan MW, Smith J, Noonberg SB & Conrad C Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. *Pediatr. Pulmonol* 42, 307–313 (2007). [PubMed: 17352404]
  45. Edson RS, Brey RH, McDonald TJ, Terrell CL, McCarthy JT & Thibert JM Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. *Mayo Clin. Proc* 79, 1185–1191 (2004). [PubMed: 15357042]
  46. Kahler DA, Schowengerdt KO, Fricker FJ, Mansfield M, Visner GA & Faro A Toxic serum trough concentrations after administration of nebulized tobramycin. *Pharmacotherapy* 23, 543–545 (2003). [PubMed: 12680485]
  47. Geller DE, Pitlick WH, Nardella PA, Tracewell WG & Ramsey BW Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. *Chest* 122, 219–226 (2002). [PubMed: 12114362]
  48. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W & Briemer DD Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. *Antimicrob. Agents Chemother* 41, 184–187 (1997). [PubMed: 8980777]
  49. Cooney GF, Lum BL, Tomaselli M & Fiel SB Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. *J. Clin. Pharmacol* 34, 255–259 (1994). [PubMed: 8021334]
  50. Cobden A et al. Audiometric threshold shifts after total knee arthroplasty by using gentamicin-loaded bone cement. *Turk. J. Med. Sci* 49, 514–518 (2019). [PubMed: 30893980]
  51. Nau R, Blei C & Eiffert H Intrathecal antibacterial and antifungal therapies. *Clin. Microbiol. Rev* 33, e00190–19 (2020). [PubMed: 32349999]

52. Kunin CM, Chalmers TC, Leevy CM, Sebastyen SC, Lieber CS & Finland M Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease. *N. Engl. J. Med* 262, 380–385 (1960). [PubMed: 14412744]
53. Pogue JM, DePestel DD, Kaul DR, Khaled Y & Frame DG Systemic absorption of oral vancomycin in a peripheral blood stem cell transplant patient with severe graft-versus-host disease of the gastrointestinal tract. *Transpl. Infect. Dis* 11, 467–470 (2009). [PubMed: 19638004]
54. Heidemuller B Ototoxicity of locally administered aminoglycoside antibiotics. *Laryngorhinootologie* 73, 331–337 (1994). [PubMed: 8060454]
55. Rohrbaugh TM, Anolik R, August CS, Serota FT & Koch PA Absorption of oral aminoglycosides following bone marrow transplantation. *Cancer* 53, 1502–1506 (1984). [PubMed: 6365302]
56. Thomas SP, Buckland JR & Rhys-Williams SR Potential ototoxicity from triamcinolone, neomycin, gramicidin and nystatin (Tri-Adcortyl) cream. *J. Laryngol. Otol* 119, 48–50 (2005). [PubMed: 15807966]
57. Yamasoba T & Tsukuda K Ototoxicity after use of neomycin eardrops is unrelated to A1555G point mutation in mitochondrial DNA. *J. Laryngol. Otol* 118, 546–550 (2004). [PubMed: 15318963]
58. Linder TE, Zwicky S & Brandle P Ototoxicity of ear drops: a clinical perspective. *Am. J. Otol* 16, 653–657 (1995). [PubMed: 8588672]
59. Pietropaolo A, Jones P, Moors M, Birch B & Somani BK Use and effectiveness of antimicrobial intravesical treatment for prophylaxis and treatment of recurrent urinary tract infections (UTIs): a systematic review. *Curr. Urol. Rep* 19, 78 (2018). [PubMed: 30094687]
60. Defoor W et al. Safety of gentamicin bladder irrigations in complex urological cases. *J. Urol* 175, 1861–1864 (2006). [PubMed: 16600780]
61. American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. *Pediatrics* 120, 898–921 (2007). [PubMed: 17908777]

TABLE 1.

## ASSIGNMENT OF MT-RNR1 PHENOTYPE BASED ON GENOTYPE

Likely phenotype	Genotypes	Example genotypes
MT-RNR1 increased risk of aminoglycoside-induced hearing loss	Individuals with a <i>MT-RNR1</i> variant associated with an increased risk of aminoglycoside-induced hearing loss	m.1095T>C m.1494C>T m.1555A>G
MT-RNR1 normal risk of aminoglycoside-induced hearing loss	Individuals with no detectable <i>MT-RNR1</i> increased risk variant or a <i>MT-RNR1</i> variant associated with normal risk of aminoglycoside-induced hearing loss	m.827A>G
MT-RNR1 uncertain risk of aminoglycoside-induced hearing loss	Individuals with a <i>MT-RNR1</i> variant associated with an uncertain risk of aminoglycoside-induced hearing loss	m.663A>G m.669T>C m.747A>G m.786G>A m.807A>G m.807A>C m.839A>G m.896A>G m.930A>G m.951G>A m.960C>del m.961T>G m.961T>del m.961T>del+Ch m.988G>A m.1189T>C m.1243T>C m.1520T>C m.1537C>T m.1556C>T

**TABLE 2.**  
RECOMMENDED THERAPEUTIC USE OF AMINOGLYCOSIDES IN RELATION TO MT-RNR1 PHENOTYPE IN CHILDREN AND ADULTS

Phenotype	Implications for phenotypic measures	Therapeutic recommendations	Classification of recommendations <sup>a</sup>	Considerations
MT-RNR1 increased risk of aminoglycoside-induced hearing loss	Very high risk of developing hearing loss if administered an aminoglycoside antibiotic	Avoid aminoglycoside antibiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).
MT-RNR1 normal risk of aminoglycoside-induced hearing loss	Normal risk of developing hearing loss if administered an aminoglycoside antibiotic.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	Individuals without <i>MT-RNR1</i> aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.
MT-RNR1 uncertain risk of aminoglycoside-induced hearing loss	Weak or no evidence for an increased risk of <i>MT-RNR1</i> -associated hearing loss if administered an aminoglycoside antibiotic.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic drug monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	Individuals without <i>MT-RNR1</i> aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.

<sup>a</sup>Rating scheme described in the Supplemental Material online.